3,802 Shares in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Purchased by Yeomans Consulting Group Inc.

Yeomans Consulting Group Inc. acquired a new stake in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,802 shares of the company's stock, valued at approximately $241,000.

A number of other large investors have also recently made changes to their positions in the stock. NBC Securities Inc. acquired a new stake in Verona Pharma PLC American Depositary Share in the 1st quarter valued at about $34,000. Vermillion Wealth Management Inc. acquired a new stake in Verona Pharma PLC American Depositary Share in the 4th quarter valued at about $46,000. GF Fund Management CO. LTD. acquired a new stake in Verona Pharma PLC American Depositary Share in the 4th quarter valued at about $72,000. Avanza Fonder AB acquired a new stake in Verona Pharma PLC American Depositary Share in the 1st quarter valued at about $100,000. Finally, GAMMA Investing LLC raised its holdings in Verona Pharma PLC American Depositary Share by 14.0% in the 1st quarter. GAMMA Investing LLC now owns 1,837 shares of the company's stock valued at $117,000 after acquiring an additional 225 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Verona Pharma PLC American Depositary Share news, CEO David Zaccardelli sold 400,000 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the sale, the chief executive officer owned 13,190,168 shares of the company's stock, valued at $150,367,915.20. This represents a 2.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark W. Hahn sold 400,000 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the completion of the transaction, the chief financial officer directly owned 12,278,992 shares in the company, valued at $139,980,508.80. This trade represents a 3.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,965,800 shares of company stock worth $20,056,881 in the last quarter. 4.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Cowen downgraded shares of Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research note on Wednesday, July 9th. TD Cowen cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 9th. Canaccord Genuity Group cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and set a $107.00 price target for the company. in a research report on Wednesday, July 9th. Wolfe Research cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. Finally, Cantor Fitzgerald upped their target price on shares of Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, June 11th. Eleven research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $109.00.

Verona Pharma PLC American Depositary Share Price Performance

Shares of VRNA remained flat at $104.90 during mid-day trading on Monday. 2,726,328 shares of the stock traded hands, compared to its average volume of 1,727,039. The company has a fifty day moving average of $87.55 and a 200-day moving average of $70.00. The company has a market cap of $8.93 billion, a PE ratio of -52.45 and a beta of 0.24. The company has a debt-to-equity ratio of 1.07, a current ratio of 8.86 and a quick ratio of 8.73. Verona Pharma PLC American Depositary Share has a 12 month low of $18.51 and a 12 month high of $105.30.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.49. The firm had revenue of $98.65 million during the quarter, compared to analysts' expectations of $41.47 million. As a group, equities analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current fiscal year.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.